Third Harmonic Bio (THRD) Stock Forecast, Price Target & Predictions
THRD Stock Forecast
Third Harmonic Bio stock forecast is as follows: an average price target of $16.15 (represents a 33.36% upside from THRD’s last price of $12.11) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
THRD Price Target
The average price target for Third Harmonic Bio (THRD) is $16.15 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $23.00 to $3.60. This represents a potential 33.36% upside from THRD's last price of $12.11.
THRD Analyst Ratings
According to 2 Wall Street analysts, Third Harmonic Bio's rating consensus is 'Buy'. The analyst rating breakdown for THRD stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Third Harmonic Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 09, 2024 | Michael Ulz | Morgan Stanley | $20.00 | $10.86 | 84.16% | 65.15% |
| Jun 17, 2024 | Alex Thompson | Stifel Nicolaus | $23.00 | $12.95 | 77.61% | 89.93% |
| Jun 07, 2024 | Laura Prendergast | Raymond James | $18.00 | $14.49 | 24.22% | 48.64% |
| Dec 16, 2022 | - | Morgan Stanley | $5.00 | $4.27 | 17.10% | -58.71% |
| Dec 16, 2022 | - | Jefferies | $3.60 | $4.30 | -16.28% | -70.27% |
The latest Third Harmonic Bio stock forecast, released on Aug 09, 2024 by Michael Ulz from Morgan Stanley, set a price target of $20.00, which represents a 84.16% increase from the stock price at the time of the forecast ($10.86), and a 65.15% increase from THRD last price ($12.11).
Third Harmonic Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $20.00 | $20.33 |
| Last Closing Price | $12.11 | $12.11 | $12.11 |
| Upside/Downside | -100.00% | 65.15% | 67.88% |
In the current month, the average price target of Third Harmonic Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Third Harmonic Bio's last price of $12.11. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 08, 2024 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| Jun 06, 2024 | Raymond James | - | Outperform | Initialise |
| Dec 16, 2022 | Morgan Stanley | - | Equal-Weight | Downgrade |
Third Harmonic Bio's last stock rating was published by Morgan Stanley on Aug 08, 2024. The company Upgrade its THRD rating from "Equal-Weight" to "Overweight".
Third Harmonic Bio Financial Forecast
Third Harmonic Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Third Harmonic Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. THRD's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Third Harmonic Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict THRD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Third Harmonic Bio's previous annual EBITDA (undefined) of $NaN.
Third Harmonic Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-12.98M | $-10.95M | $-11.36M | $-14.19M | $-13.05M | $-12.13M | $-11.64M |
| High Forecast | $-12.98M | $-10.95M | $-11.36M | $-14.19M | $-13.05M | $-10.56M | $-11.64M |
| Low Forecast | $-12.98M | $-10.95M | $-11.36M | $-14.19M | $-13.05M | $-14.09M | $-11.64M |
| Surprise % | - | - | - | - | - | - | - |
Third Harmonic Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. THRD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Third Harmonic Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Third Harmonic Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to THRD last annual SG&A of $NaN (undefined).
Third Harmonic Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.32 | $-0.27 | $-0.28 | $-0.35 | $-0.32 | $-0.30 | $-0.29 |
| High Forecast | $-0.32 | $-0.27 | $-0.28 | $-0.35 | $-0.32 | $-0.26 | $-0.29 |
| Low Forecast | $-0.32 | $-0.27 | $-0.28 | $-0.35 | $-0.32 | $-0.35 | $-0.29 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Third Harmonic Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to THRD previous annual EPS of $NaN (undefined).
Third Harmonic Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.64 | $24.75 | 1409.15% | Buy |
| SNSE | Sensei Biotherapeutics | $0.52 | $5.50 | 957.69% | Buy |
| PASG | Passage Bio | $0.60 | $6.00 | 900.00% | Buy |
| HOWL | Werewolf Therapeutics | $2.26 | $12.00 | 430.97% | Buy |
| NUVB | Nuvation Bio | $2.29 | $6.75 | 194.76% | Buy |
| ACRV | Acrivon Therapeutics | $7.85 | $22.00 | 180.25% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| NXTC | NextCure | $1.31 | $3.00 | 129.01% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| THRD | Third Harmonic Bio | $12.11 | $16.15 | 33.36% | Buy |
| EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
| GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
| RVMD | Revolution Medicines, Inc. Warrant | $55.87 | $58.57 | 4.83% | Buy |
THRD Forecast FAQ
Is Third Harmonic Bio a good buy?
Yes, according to 2 Wall Street analysts, Third Harmonic Bio (THRD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of THRD's total ratings.
What is THRD's price target?
Third Harmonic Bio (THRD) average price target is $16.15 with a range of $3.6 to $23, implying a 33.36% from its last price of $12.11. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Third Harmonic Bio stock go up soon?
According to Wall Street analysts' prediction for THRD stock, the company can go up by 33.36% (from the last price of $12.11 to the average price target of $16.15), up by 89.93% based on the highest stock price target, and down by -70.27% based on the lowest stock price target.
Can Third Harmonic Bio stock reach $20?
THRD's highest twelve months analyst stock price target of $23 supports the claim that Third Harmonic Bio can reach $20 in the near future.
What are Third Harmonic Bio's analysts' financial forecasts?
Third Harmonic Bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-36.814M (high $-35.249M, low $-38.771M), average SG&A $0 (high $0, low $0), and average EPS is $-0.908 (high $-0.869, low $-0.956). THRD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-49.478M (high $-49.478M, low $-49.478M), average SG&A $0 (high $0, low $0), and average EPS is $-1.22 (high $-1.22, low $-1.22).